Related Experiment Videos
Lonidamine: an overview
1Institute of Pharmacology, University La Sapienza, Rome, Italy.
Abstract:
The attention of pharmaco-therapeutic research is shifting from the cell duplication mechanisms to the oncogene expressions and cofactors that are the actual cause of cancer. This trend corresponds to the appearance of a second generation of anticancer agents that are typically represented by tamoxifen and lonidamine. The first is a hormonal agent with endocrine effect that was developed making use of a rationale and methods already available, although in a different context. The second, an energolytic agent, is a more complicated case. It was discovered when neither a solid knowledge of cancer energy systems nor the related pharmacological methods were available. Both had to be developed along with a basic research in which lonidamine was at the same time target and tool. In this way, the indication was obtained that cancer activates a specialized energy system in the repair phase following exposure to hyperthermia, alkylating agents, and radiations. This system confers cancer cells an advantage over the normal ones, but is vulnerable and appears to be lonidamine's target. The presently available data show that lonidamine, when used in appropriate conditions with respect to its mode of action, increases the disease-free interval and survival in some types of tumours.
Insights
Researchers are exploring new cancer treatments targeting oncogene expressions. Lonidamine, an energolytic agent, shows promise by targeting a specialized cancer cell energy system, improving survival rates in certain tumors.
Area of Science:
- Oncology
- Pharmacology
- Cancer Biology
Background:
- Cancer research is shifting focus from cell duplication to oncogene expressions and cofactors.
- A new generation of anticancer agents, including tamoxifen and lonidamine, has emerged.
- Lonidamine's discovery necessitated parallel development of cancer energy system knowledge and pharmacological methods.
Purpose of the Study:
- To investigate the role of a specialized energy system in cancer cell survival and repair.
- To evaluate lonidamine as a therapeutic agent targeting this cancer-specific energy system.
- To assess the impact of lonidamine on disease-free interval and survival in tumor types.
Main Methods:
- Basic research into cancer energy metabolism, particularly the repair phase post-treatment.
- Utilizing lonidamine as both a research tool and therapeutic target.
- Clinical evaluation of lonidamine's efficacy under specific conditions related to its mode of action.
Main Results:
- Cancer cells activate a specialized energy system during repair after hyperthermia, alkylating agents, and radiation.
- This system provides a survival advantage to cancer cells but is vulnerable to lonidamine.
- Lonidamine demonstrated an increase in disease-free interval and survival for certain tumor types.
Conclusions:
- Lonidamine targets a vulnerable, cancer-specific energy system crucial for cell repair.
- Targeting this energy system represents a promising therapeutic strategy in oncology.
- Optimized use of lonidamine can improve patient outcomes in specific cancer types.